期刊
REGENERATIVE MEDICINE
卷 10, 期 2, 页码 193-209出版社
FUTURE MEDICINE LTD
DOI: 10.2217/RME.14.86
关键词
animal model; clinical trial; GSK-3 inhibitor; HDAC inhibitor; neurogenesis; neuroprotection; secondary injury; spinal cord injury; valproic acid
资金
- National Natural Science Foundation of China [81330042]
Spinal cord injury (SCI) is difficult to treat because of secondary injury. Valproic acid (VPA) is clinically approved for mood stabilization, but also counteracts secondary damage to functionally rescue SCI in animal models by improving neuroprotection and neurogenesis via inhibition of HDAC and GSK-3. However, a comprehensive review summarizing the therapeutic benefits and mechanisms of VPA for SCI and the issues affecting clinical trials is lacking, limiting future research on VPA and impeding its translation into clinical therapy for SCI. This article presents the current status of VPA treatment for SCI, emphasizing interactions between enhanced neuroprotection and neurogenesis. Crucial issues are discussed to optimize its clinical potential as a safe and effective treatment for SCI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据